Abasaglar ® (basal insulin glargine)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).

Abasaglar® (insulin glargine): use in patients with COVID-19 (coronavirus disease 2019)

The use of Abasaglar in patients with COVID-19 has not been studied.

Use of Abasaglar in a Patient With COVID-19

COVID-19 is an infectious respiratory disease caused by SARS-CoV-2, previously referred to as "2019 novel coronavirus."1

Lilly has not studied the use of Abasaglar in patients with COVID-19 nor in patients at risk of contracting COVID-19.

According to the label, respiratory infections are not listed as a warning or precautions for use of Abasaglar.2

Clinicians should use their clinical judgment to determine the most appropriate approach to use Abasaglar in a patient who has confirmed or suspected COVID-19.

Infectious Disease Resources for COVID-19

For current information on COVID-19, please refer to


1. Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health Organization. Accessed March 17, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it

2. Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

3. Coronavirus disease (COVID-19) outbreak. European web page of the World Health Organization. Accessed March 20, 2020. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19

4. International Diabetes Federation Europe. COVID-19 outbreak: guidance for people with diabetes. https://www.idf.org/our-network/regions-members/europe/europe-news/196-information-on-corona-virus-disease-2019-covid-19-outbreak-and-guidance-for-people-with-diabetes.html. Accessed March 18, 2020

5. COVID-19. European Centre for Disease Prevention and Control. Accessed March 20, 2020. https://www.ecdc.europa.eu/en/novel-coronavirus-china


Abasaglar = Abasaglar® (insulin glargine) 100 units/mL

COVID-19 = coronavirus disease 2019

ECDC = European Centre for Disease Prevention and Control

EU WHO = World Health Organization (European regional office)

Lilly = Eli Lilly and Company

SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2

Date of Last Review: 17 March 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request